GHK-Cu — the copper-binding tripeptide glycyl-L-histidyl-L-lysine bound to copper — is one of the most-studied peptides in skin, wound, and tissue-regeneration research. It occurs naturally in human plasma and declines with age, which is part of why it has drawn sustained research interest. This overview is for educational reference only.
What is GHK-Cu?
GHK-Cu is a small copper-carrier peptide. In the research literature it is examined for its role in extracellular-matrix remodeling, copper transport, and signaling related to skin and connective tissue. It is supplied as a lyophilized powder (often pale blue due to its copper content).
Research focus areas
- Skin remodeling: studied in collagen and extracellular-matrix research models.
- Wound research: examined in tissue-repair and regeneration pathways.
- Antioxidant and copper-transport signaling: investigated for its role in delivering copper to cells.
Handling and quality
Reconstitute lyophilized GHK-Cu with bacteriostatic water for research handling. Because GHK-Cu is frequently studied alongside other recovery peptides, researchers also use the combined BPC-157 + GHK-Cu + TB-500 blend. Always confirm identity and purity via a batch-specific Certificate of Analysis.
For laboratory and research use only. Not for human or animal consumption. This article summarizes publicly available research and is not medical advice.
The short version
Everything difficult about this material follows from one fact: it is a coordination complex rather than a plain peptide, so a vial contains an organic ligand, a copper(II) center, a counter-ion and whatever water came along with them. That changes the meaning of the number on the label, because a stated milligram figure describes a formula unit and not a quantity of peptide. It changes what a certificate can settle, because a peptide purity figure characterizes the ligand and is silent on whether the metal is bound, how much of it is present, or whether any of it is loose. It changes bench behavior, because chelators, phosphate, citrate and reducing agents all compete for the copper and can quietly take it. And it changes how the skin and tissue literature should be read, because an experiment run without a copper control cannot separate the peptide from the metal it carries. The sections below work through each of those in order.
What a milligram figure on a metal-complex label promises
A quantity printed on a peptide container has one natural reading: that much peptide, give or take the salt and water that every lyophilized powder carries. For a copper complex the same printed quantity has at least three readings, and they are not close to each other.
The first reading is that the figure describes the complex as supplied, so the weighed powder is the whole formula unit and the peptide is only a fraction of it. The second is that the figure describes the peptide content, with the copper counted separately or not counted at all. The third is that the figure describes a specific salt or hydrate of the complex, in which case a counter-ion and crystal water are inside the number as well. Three vendors can each be internally consistent, print the same figure, and be describing materially different amounts of the same active species.
The components that make up the mass are easy to enumerate and hard to measure without asking for the right documents. There is the tripeptide ligand itself. There is the copper(II), which is a non-trivial share of the formula weight because a single metal atom is heavy relative to three small amino acid residues. There is a counter-ion, because a charged complex has to be balanced by something, and the identity of that counter-ion depends on how the material was worked up. There is residual water, because these powders are hygroscopic and because hydrates are common for metal complexes. And there may be residual salts left over from synthesis and purification that nobody itemized.
The consequence bites hardest at the point where most published work actually lives, which is a molar concentration in a medium. Converting a weighed mass into a molar concentration requires a formula weight for the thing that was weighed, not for the idealized complex in a textbook. If the material is a hydrated salt and the calculation used the anhydrous free complex, the prepared concentration is lower than the recorded one, and the error is systematic rather than random: every experiment in that series carries it in the same direction.
The point that follows from all of this, and that a peptide-only document never addresses, is that copper content is a specification in its own right. It is not implied by the compound name, it is not implied by a purity percentage, and it does not fall out of a mass spectrum run under conditions that dissociate the complex. It is a separate number produced by a separate method, and its absence from a certificate is a gap rather than a formality.
Illustrative mass accounting for a nominal 100 mg of a copper tripeptide complex. The figures are round placeholders chosen to show the shape of the calculation; they are not values for any lot and should never be used in place of a lot-specific document.
| Component of the weighed powder | Illustrative share of 100 mg | Why it is present |
|---|---|---|
| Tripeptide ligand | 72 mg | The organic part, and the only part a peptide purity figure describes |
| Copper(II) | 14 mg | The metal center; a single heavy atom against three small residues |
| Counter-ion | 9 mg | Charge balance, with the identity set by the workup chemistry |
| Water | 4 mg | Hydrate water plus moisture picked up by a hygroscopic powder |
| Unitemized residual salts | 1 mg | Leftovers from synthesis and purification that no field reports |
| Peptide actually present | 72 mg, not 100 mg | The number a molar calculation needs and the label does not give |
Read the last row as the whole argument in miniature. Nothing in that table is unusual chemistry, and nothing in it is hidden by anyone acting badly; it is just what a formula unit looks like when a metal is inside it. The practical response is to treat the label figure as a gross mass, ask separately for peptide content and for copper content, and record in the notebook which of the three readings the calculation assumed. A concentration that cannot be traced back to a stated formula weight is a number without a basis.
Complexed versus uncomplexed material is the real quality question
A certificate showing high purity for the tripeptide is a genuine piece of evidence, and it is evidence about the ligand. It establishes that the organic material in the vial is predominantly one species and, if a mass measurement accompanies it, that the species has the expected sequence mass. It says nothing whatsoever about the metal, and there is a reason that gap is easy to miss: the compound name contains the metal, so the document appears to be about a copper complex when the measurement underneath it was not.
At least four distinct states of a vial are consistent with the same clean peptide chromatogram. The material may be a properly constituted complex at the intended metal-to-ligand ratio. It may be under-metalated, a mixture of complex and free tripeptide, which behaves as a weaker preparation at the same weighed mass. It may carry excess copper beyond what the ligand can hold, present as a free salt, which is the state with real experimental consequences discussed in a later section. Or the copper site may be partly occupied by a different metal picked up from reagents or glassware, which is invisible to every peptide-side measurement.
The methods that close that gap are orthogonal to peptide analytics, which is precisely why the standard package does not include them. Total metal determination on a digested sample, by atomic absorption or by inductively coupled plasma methods, answers how much copper is in the vial without reference to the peptide at all, and the plasma methods have the additional advantage of reporting other metals in the same run, which is how displacement by iron or zinc becomes visible. Combining a total copper figure with a peptide content figure gives a ratio, and a ratio is stoichiometry rather than an assumption.
Total metal does not, however, tell you that the metal is coordinated. For that the useful observable is the complex's own visible absorbance. Copper(II) in a nitrogen-rich coordination environment produces a d-d transition in the visible region, so a solution of the intact complex is blue, and the absorbance arises from the coordination sphere rather than from the peptide backbone. A spectrophotometric measurement of that band reports on coordination in a way that a total metal number cannot. Visual color is the crude version of the same observation, free, immediate, and worth exactly as much as any qualitative check: it can tell you something is wrong, and it cannot tell you that everything is right.
Note also what standard peptide chromatography does to this question. Reversed- phase methods for peptides are usually run in acid, and acid dissociates the complex, so the chromatogram is largely a chromatogram of the free ligand. The general problem of running a very short peptide through routine analytics is covered in the KPV overview linked below and is not rebuilt here; the point specific to this material is narrower and more awkward, which is that the method used to produce the purity figure actively destroys the thing the label names.
What each quality question needs, and what a peptide-only certificate says about it
| Question about the vial | Method that answers it | What a peptide-only COA shows |
|---|---|---|
| Is the ligand the right sequence? | Mass measurement against the theoretical sequence mass | Answered, and answered well |
| How much of the organic material is that sequence? | Chromatographic purity by area | Answered, subject to the usual method caveats |
| How much copper is in the vial? | Elemental analysis; atomic absorption or plasma-source methods | Silent |
| Is the copper actually coordinated? | Visible absorbance of the d-d band; color as a crude proxy | Silent |
| Is any copper present as a free salt? | Total copper read against peptide content to give a ratio | Silent |
| Has another metal displaced the copper? | Multi-element plasma analysis on a digested sample | Silent |
| How much of the weighed powder is peptide? | Peptide content or net peptide assay | Usually absent unless requested |
Four silences out of seven is the reason a peptide-only certificate is an incomplete document for this material rather than a bad one. It answers its own questions properly and was never designed to answer the others. The reasonable request to a supplier is therefore not a complaint about the certificate but an addition to it: a lot-specific copper determination, stated with the method used, alongside the peptide figures already provided. Suppliers who commission that work have it on file; suppliers who do not will say so, which is itself useful information about what the name on the label was based on.
Buffer and additive choices that quietly strip the copper
Once the material is in solution, the copper is no longer held by the ligand alone. It is held by the ligand in competition with every other potential donor in the vessel, and coordination chemistry does not respect the intent of the experiment. A complex that is entirely stable in water can be substantially disassembled in a buffer chosen for unrelated reasons, and nothing about that process announces itself unless somebody looks.
The first variable is pH, and it is the one most often overlooked because plain peptides are comparatively indifferent to it across the working range. Copper binding by this ligand involves deprotonation of a backbone amide nitrogen, and amide nitrogens do not give up a proton on their own; they do so because the metal center stabilizes the resulting anion. Lower the pH and that stabilization is progressively lost, the amide takes its proton back, and the complex comes apart. Raise the pH far enough and a different failure appears, because copper hydroxide precipitates from alkaline solution. The intact complex therefore occupies a window rather than a floor, and a preparation moved from one medium to another has moved within that window whether or not anyone recorded it.
The second variable is competition from deliberate additives. Aminopolycarboxylate chelators, of which EDTA is the everyday example, bind copper(II) far more tightly than a tripeptide does. Adding EDTA to a solution of this complex does not moderate it or stabilize it; it converts it into free ligand plus a copper-EDTA species. Citrate is a weaker but real competitor and appears in more buffers than people expect. Phosphate is a double problem, because it coordinates weakly and because copper phosphate is poorly soluble, so the failure can show up as turbidity or as a slow loss of color with no obvious cause.
The third variable is competition from things nobody thinks of as additives. Tris carries a primary amine and is a known coordinator of copper(II). Free histidine, which appears in defined media and in amino acid supplements, is an excellent copper ligand and will exchange readily. Serum albumin carries a high-affinity N-terminal copper site, so serum-containing medium is a copper exchange environment by construction, not an inert background. Thiols are a separate category again, because cysteine, dithiothreitol and related reagents reduce copper(II) to copper(I), and the donor set that stabilizes the divalent ion does not stabilize the monovalent one. Ascorbate does the same thing by a different route.
None of this makes the material difficult to work with. It makes buffer choice a deliberate decision with a stated rationale rather than a default inherited from a peptide protocol, and it makes the visible color of the working solution worth a glance every time it is prepared.
Common buffer components and additives, and how each interacts with a copper(II) tripeptide complex
| Buffer or additive | Interaction with the complex | Practical consequence on a bench |
|---|---|---|
| EDTA and related chelators | Bind copper(II) far more strongly than the tripeptide | Quantitative stripping; the solution becomes free ligand plus a copper chelate |
| Citrate | Moderate competing coordination | Partial disassembly that scales with citrate concentration |
| Phosphate | Weak coordination plus a poorly soluble copper salt | Fading color, haze, or a precipitate at neutral to alkaline pH |
| Tris | Primary amine coordinates copper(II) | Slow equilibrium shift toward a copper-Tris species |
| Free histidine in defined media | Strong, fast copper coordination | Exchange that is complete before the experiment begins |
| Serum albumin | High-affinity N-terminal copper site | Serum-containing medium is a copper exchange environment, not a blank |
| Ascorbate, DTT, TCEP, cysteine | Reduce copper(II) to copper(I) | Complex is destroyed and the released metal becomes redox-active |
The through-line across those rows is that copper is a shared resource in solution and the tripeptide is only one of several claimants. Two habits make the difference in practice. Write down the full composition of the working medium, including the parts inherited from a supplier formulation rather than added deliberately, and read that composition specifically for donor atoms and reductants. Then look at the solution. A preparation that should be blue and is not has already answered a question that would otherwise take an instrument to ask.
Free copper as an interference in cell-based experiments
The reason uncomplexed copper matters is not that it is an impurity in the bookkeeping sense. It is that copper ions are chemically active in exactly the way that produces convincing-looking biology. Copper cycles between two oxidation states, and in the presence of a reductant and any peroxide it participates in Fenton-type chemistry that generates hydroxyl radicals. Culture medium is not a neutral setting for that: it commonly contains ascorbate or other reducing species, and cells generate peroxide as ordinary metabolism.
The observable consequences of a small amount of loosely bound copper are the same observables that most experiments in this area are set up to measure. Oxidative stress shifts transcription broadly. It changes proliferation and migration rates. It alters matrix protein output and the activity of enzymes that turn matrix over. A concentration-response curve produced by free copper looks like a concentration-response curve produced by anything else, and a plate reader does not distinguish the mechanism. This is the specific way an attribution error enters this literature: not through fraud or carelessness, but because the interfering species is delivered in the same vial as the compound of interest and in a proportion nobody measured.
A properly controlled experiment with this material therefore carries more arms than a peptide experiment does. The essential one is a copper salt control at matched total copper concentration, which is the arm that separates the metal from the ligand. Matched means matched on copper, not on mass and not on the nominal concentration of the complex, which is why the copper determination from the previous section is a prerequisite rather than a nicety. The second arm is the free tripeptide without metal, which is what shows whether the ligand contributes anything on its own. The third is the vehicle, prepared identically, including any acid used to get the powder into solution.
Two further arms are worth running when the readout is anything oxidative-stress adjacent. A copper-selective chelator arm, added alongside the complex, tests whether an observed effect survives removal of the labile metal. And a medium-only copper background measurement establishes what the cells were already exposed to, since serum and some defined supplements contribute copper independently of anything anyone added.
The uncomfortable observation is that a substantial share of the cell-based work in this corpus reports only the complex and a vehicle. Those experiments are not worthless; they establish that the preparation did something under the stated conditions. They simply cannot attribute what happened to the tripeptide, and any write-up that cites them as evidence for the peptide has made a claim the design does not support. Checking the methods section for a copper arm is a five-second filter that changes how a large fraction of the literature should be described.
Control arms for a cell-based experiment with a copper peptide complex
| Control arm | What it establishes | What its absence permits |
|---|---|---|
| Copper salt at matched copper concentration | Whether the metal alone reproduces the effect | Attributing a metal effect to the peptide |
| Free ligand with no metal | Whether the peptide contributes independently | Assuming the ligand is inert or assuming it is active |
| Vehicle prepared identically | That the solvent and any acid are not the variable | A solvent artifact reported as compound activity |
| Copper-selective chelator alongside the complex | Whether the effect survives removal of labile metal | Loose copper masquerading as a coordinated-metal effect |
| Medium-only copper background | The exposure the cells already had | Treating a small added increment as the whole exposure |
| Stated copper determination for the lot | That the matched concentration was actually matched | A copper control matched to a number nobody measured |
Every row in that table is an experiment somebody has to run, which is a real cost, and that cost is the honest explanation for why so many published designs omit them. It is still the case that the omission changes what a result means. When summarizing a study of this compound, the useful sentence is not whether an effect was reported but which of these arms the design included, because that determines whether the finding belongs to the peptide, to the copper, or to the preparation as an undifferentiated whole.
Reading the skin and tissue corpus by evidence tier
The body of published work touching this compound and connective tissue is large and old, and its size is misleading, because count of papers and weight of evidence are only loosely related here. Sorting the corpus by what kind of study a claim came from does more to clarify it than sorting by topic.
Most of it is in vitro. Monolayer cultures of dermal fibroblasts and keratinocytes, with proliferation, migration, matrix protein output and enzyme activity as endpoints, make up the bulk of the mechanistic literature. These are informative about what a preparation does to cells in a dish under a defined set of conditions, and their weakness is the one described in the previous section: the conditions frequently leave the copper unaccounted for. Ex vivo work on tissue explants adds architecture and cell-cell context and is closer to a real tissue, but it remains a preparation in a controlled environment with a limited viable window.
Animal injury models are the part of the record that most resembles conventional preclinical work, with defined models, scored endpoints and histology. They are also where formulation dependence becomes acute, because whatever was applied to the animal was a formulation, and the vehicle affects how much intact complex reached the tissue. Two studies reporting different outcomes may differ in vehicle rather than in biology, and vehicle composition is often described in one sentence or not at all.
Transcriptional profiling occupies a distinct tier and is frequently over-interpreted. There is a well-known set of analyses reporting broad expression shifts in fibroblasts exposed to the complex, sometimes framed by comparison against reference expression databases. The correct reading of such a dataset is that transcript abundance changed, which is a hypothesis about function rather than a demonstration of one. The distance between those two statements is where most of the confident secondary writing about this compound lives.
Two structural features of the corpus deserve to be stated plainly and without insinuation. The first is that a large share of it, including several of the most-cited reviews, traces to a small number of research programs with continuous involvement in the field since the compound was first isolated. That is a normal consequence of a specialized area and it is not evidence of anything improper, but it does mean that a claim repeated across many papers may have fewer independent origins than the citation count suggests. The second is that a substantial fraction of the material circulating as evidence comes from cosmetic-industry sources: formulation and stability studies, which are genuinely useful because they address whether the complex survives in a real matrix, and sponsor-funded evaluations of multi-ingredient finished preparations, which cannot attribute an outcome to any single component. Both are legitimate documents in their own context. Neither characterizes the isolated complex, and citing them as though they did is the most common failure in write-ups on this subject.
Study types in this corpus and the strongest claim each can support
| Source type | Typical readout | Strongest claim it supports |
|---|---|---|
| Cell monolayer culture | Proliferation, migration, matrix output, enzyme activity | A preparation altered a cellular readout under stated conditions |
| Ex vivo tissue explant | Histology and matrix composition with tissue architecture intact | The same, in a preparation retaining tissue structure for a limited window |
| Animal injury model | Scored closure, tensile properties, histology | An effect in a defined model, inseparable from the vehicle used |
| Transcriptional profiling | Differential expression against a control condition | Transcript abundance changed; a hypothesis about function, not a demonstration |
| Formulation and stability study | Complex integrity, color, metal content in a matrix over time | How the material behaves in that specific matrix |
| Sponsor-funded finished-preparation evaluation | Instrumented or scored endpoints on a multi-ingredient product | Something about that product; nothing attributable to one ingredient |
| Secondary review or vendor document | Restated claims with citations to the above | Nothing on its own; it is a pointer to primary work, at best |
The discipline that follows is small and worth keeping. When a claim about this compound appears, find which row of that table it came from before deciding how to phrase it, and check whether the primary source specified which species was used and how the copper was accounted for. Claims that survive both checks are worth citing precisely. Claims that fail either one are still worth recording, but they should be described as what they are, which is a reported observation under conditions that do not isolate the variable of interest.
What the different copper peptide label strings denote
Because this compound sits at the junction of peptide chemistry, coordination chemistry and cosmetic ingredient nomenclature, it accumulated several parallel naming conventions, and documents from those three worlds do not use the same one. Reading a paper, a specification sheet or a supplier listing therefore starts with working out which convention is in play, because two of the strings in circulation denote chemically different species.
The bare sequence abbreviation, three letters for the three residues, denotes the free tripeptide with no metal. Some papers, particularly older ones written before the metal-binding property reframed the compound, use that string while describing experiments in serum-containing medium, where free ligand acquires copper from albumin and other sources. In that situation the name is accurate about what was weighed and inaccurate about what acted, and the only honest description in a write-up is to say so.
The hyphenated form with the metal symbol denotes the complex, and modern work generally uses it deliberately to force the distinction. It is still a name rather than a measurement: it commits the writer to having intended a complex and commits nobody to having verified the copper content.
The cosmetic ingredient nomenclature name, copper tripeptide-1, is the string used in ingredient declarations and much of the formulation literature. It refers to the same complex, but the documents it appears in are usually about a finished matrix rather than an isolated material, and an ingredient declaration establishes presence, not concentration, and certainly not that the complex is still intact in the product.
The generic phrase copper peptide is a category rather than a compound and should be treated as unresolved until a sequence appears. It covers this tripeptide, it covers other metal-binding sequences such as the alanine-substituted tripeptide that also circulates as a copper complex, and it covers proprietary preparations whose composition is not disclosed. A study of a copper peptide preparation is not a study of this compound unless the paper says which one.
Blends are the last category and the hardest to reason about. Preparations combining this complex with unrelated peptides raise the ordinary attribution problem, which is that nothing observed can be assigned to one component without single-component arms, plus a chemical problem specific to a metal complex: the other peptides and any excipients present are themselves potential ligands and potential reductants for the copper center. A blend is not this material plus other materials; it is a different solution chemistry that happens to contain this material.
Label strings in circulation and what each one commits the document to
| String as it appears | What it usually denotes | What to establish before relying on it |
|---|---|---|
| GHK | The free tripeptide, no metal | Whether the medium supplied copper regardless of what was weighed |
| GHK-Cu | The copper(II) complex, as an intention | A lot-specific copper determination and stated stoichiometry |
| Copper tripeptide-1 | The same complex, in ingredient nomenclature | Whether the document describes an isolated material or a finished matrix |
| Copper peptide | A category, not a compound | The actual sequence; treat as unresolved until stated |
| Copper peptide in a topical vehicle | A formulation, with the complex as one component | Whether the complex is intact in that matrix and at what concentration |
| Multi-peptide blend containing the complex | A different solution chemistry containing this material | Single-component arms, plus what else in the blend can bind or reduce copper |
| A salt or hydrate form named on a specification | A specific weighable solid | Which formula weight the molar arithmetic should use |
The reason to be pedantic about strings here is that the difference between two of them is a metal atom, and a metal atom is the whole subject. A note that records the exact string used by each source, rather than normalizing everything to one preferred name while reading, preserves information that is genuinely hard to recover later. It also makes it obvious when a chain of citations has silently crossed from one species to another, which happens in this corpus more often than in most.
Questions this guide gets asked
Does a purity percentage on this material describe the complex or the peptide?
The peptide, in almost every case. Purity by area is produced by reversed-phase chromatography, those methods are usually run under acidic conditions, and acid dissociates this complex, so the material presented to the detector is largely free ligand. That makes the figure a real and useful characterization of the organic component and not a characterization of the coordination complex named on the label. The practical implication is that two lots with identical purity figures can differ in copper content by a wide margin, and nothing in the chromatogram would reveal it. A copper determination by an elemental method is the measurement that addresses the metal, and it has to be requested separately.
How can a lab establish copper content without an in-house elemental method?
By requesting it from the supplier as a lot-specific figure with the method stated, or by sending a sample to a contract laboratory that runs atomic absorption or plasma-source elemental analysis. Both are routine services and neither requires specialized sample handling beyond an ordinary digestion. The answer worth avoiding is inference from the compound name, from the purity figure, or from a mass spectrum, because none of those constrain the metal content. A cheap partial check available to any lab is the visible absorbance of the working solution, which reports on whether copper is coordinated even though it does not report how much total copper is present.
Is one copper per peptide safe to assume when calculating a molar concentration?
It is the intended stoichiometry and it is not a measurement. Preparations that are under-metalated, and preparations carrying copper in excess of what the ligand holds, are both consistent with a clean peptide certificate, so the assumption can be wrong in either direction. For work where the copper concentration matters, which includes anything with an oxidative-stress-adjacent readout, the ratio should come from a total copper figure read against a peptide content figure rather than from the formula. Where that data is unavailable, the honest approach is to record the assumption explicitly in the method notes so that a later reader can see which numbers were measured and which were inherited from the name.
A paper reports a concentration in micromolar but does not say which species was used. How should that be read?
As an unresolved variable rather than a minor omission. Free tripeptide and the copper complex are different chemical species with different formula weights, so a stated molar concentration maps to different weighed masses depending on which was used. Worse, in serum-containing medium free ligand acquires copper from albumin and other sources, so even a paper that weighed free peptide may have run the experiment on a partly complexed species. When summarizing such a study, the defensible phrasing states the reported concentration, names the species as the paper named it, and notes that the metal status of the material during the experiment was not established. That is less satisfying than a clean citation and considerably more accurate.
Can this material be worked with in phosphate-buffered saline?
It is a common choice and it is not a neutral one. Phosphate coordinates copper weakly and copper phosphate has poor solubility at neutral to alkaline pH, so a preparation in phosphate buffer can lose color, develop haze, or drop a precipitate over time without anything else changing. Whether that matters depends on the concentration involved and the timescale of the experiment, and it is the kind of thing to check empirically for a specific preparation rather than assume in either direction. The general principle is that buffer choice for a metal complex is a chemistry decision requiring a rationale, not a default carried over from a peptide protocol, and that the visible color of the solution is a free ongoing check.
Why do two specification sheets for the same compound list different formula weights?
Usually because they describe different solid forms. A free complex, a salt of that complex, and a hydrate of either are all weighable materials with different formula weights, and a specification sheet that does not name the form leaves the reader to guess which basis was used. The gap is not academic: a molar concentration computed from the wrong formula weight is systematically off, in the same direction, for every preparation made from that lot. When two documents disagree, the question to ask the supplier is which solid form the figure describes and whether a water content determination exists for the lot, rather than which of the two numbers is correct.
How should a claim that originated in a cosmetic-industry publication be described?
By its actual provenance, without either dismissing it or upgrading it. Formulation and stability work from that sector is often technically sound and is the best available evidence on whether the complex survives in a given matrix, which is a real question no academic paper tends to address. Evaluations of finished multi-ingredient preparations are a different matter, because no design that varies a whole product can attribute an outcome to one component. The useful description names the study type, notes the sponsor relationship where it is disclosed, and states what the design can support. The failure to avoid is letting a claim travel from a product evaluation into a sentence about the isolated complex, which is how most of the confident secondary writing on this subject was assembled.
Where to read next
- KPV research overview: a short peptide through routine analytics why very short sequences strain standard chromatographic methods
- How to review a peptide certificate of analysis the field-by-field walkthrough this guide assumes
- Purity versus identity for research-use laboratories why an area percentage and a mass measurement are not interchangeable
- Research peptide blends explained the attribution problem when a metal complex is one component of several
- GHK-Cu 100 mg specification page, with the coordination chemistry set out in detail
- Third-party lab testing and COAs
All materials referred to here are supplied strictly for laboratory research use. They are not drugs, cosmetics, foods, or medical devices, and they are not for human or veterinary use, diagnostic use, or any form of consumption or application to people or animals. Nothing above describes what this or any compound does in a person, and nothing above is guidance for preparing or using any material outside a controlled research setting. Analytical and chemical descriptions are general explanations of published laboratory practice.